Dynavax Technologies Overview
- Year Founded
-
1996
- Status
-
Acquired/Merged
- Employees
-
405
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$2.2B
Dynavax Technologies General Information
Description
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Contact Information
Website
www.dynavax.com(Operating Subsidiary)
Corporate Office
- 2100 Powell Street
- Suite 720
- Emeryville, CA 94608
- United States
Corporate Office
- 2100 Powell Street
- Suite 720
- Emeryville, CA 94608
- United States
Dynavax Technologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Merger/Acquisition | 10-Feb-2026 | $2.2B | Completed | Profitable | ||
| 17. Debt Refinancing | 05-Mar-2025 | Completed | Generating Revenue | |||
| 16. PIPE | 31-Aug-2024 | Completed | Generating Revenue | |||
| 15. Secondary Transaction - Open Market | 09-Feb-2023 | Completed | Generating Revenue | |||
| 14. Secondary Transaction - Open Market | Completed | Generating Revenue | ||||
| 13. PIPE | 12-Aug-2019 | Completed | Generating Revenue | |||
| 12. General Corporate Purpose | 12-Mar-2018 | Completed | Generating Revenue | |||
| 11. PIPE | 22-Jul-2015 | Completed | Generating Revenue | |||
| 10. 2PO | 21-Jul-2015 | $125M | $263M | Completed | Generating Revenue | |
| 9. Debt - General | 29-Dec-2014 | $145M | Completed | Generating Revenue |
Dynavax Technologies Comparisons
Industry
Financing
Details
Dynavax Technologies Competitors (41)
One of Dynavax Technologies’s 41 competitors is Valerio Therapeutics, a Formerly VC-backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Valerio Therapeutics | Formerly VC-backed | Paris, France | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| VBI Vaccines | Corporation | Cambridge, MA | ||||
| Zymeworks | Formerly VC-backed | Vancouver, Canada |
Dynavax Technologies Patents
Dynavax Technologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026525284-A | Lyme disease vaccine containing adjuvant and borrelia cell surface protein a antigen | Pending | 10-Jul-2023 | ||
| AU-2024287849-A1 | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen | Pending | 10-Jul-2023 | ||
| EP-4743109-A1 | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen | Pending | 10-Jul-2023 | ||
| WO-2025015042-A1 | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen | Inactive | 10-Jul-2023 | ||
| EP-4743110-A1 | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens | Pending | 10-Jul-2023 | A61K39/39 |
Dynavax Technologies Signals
Dynavax Technologies Former Investors (38)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Majority | ||
| Axiom Venture Partners | Venture Capital | Minority | ||
| Azimuth Opportunity | Investment Bank | Minority | ||
| BVCF | Venture Capital | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority |
Dynavax Technologies Acquisitions (2)
Dynavax Technologies’s most recent deal was a Merger/Acquisition with Symphony Dynamo for . The deal was made on 04-Jan-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Symphony Dynamo | 04-Jan-2010 | Merger/Acquisition | Pharmaceuticals | ||
| Rhein Biotech | Merger/Acquisition | Pharmaceuticals |
Dynavax Technologies ESG
Risk Overview
Risk Rating
Updated November, 30, 2025
29.63 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Biotechnology
Subindustry
of 434
Rank
Percentile
Dynavax Technologies FAQs
-
When was Dynavax Technologies founded?
Dynavax Technologies was founded in 1996.
-
Where is Dynavax Technologies headquartered?
Dynavax Technologies is headquartered in Emeryville, CA.
-
What is the size of Dynavax Technologies?
Dynavax Technologies has 405 total employees.
-
What industry is Dynavax Technologies in?
Dynavax Technologies’s primary industry is Drug Discovery.
-
Is Dynavax Technologies a private or public company?
Dynavax Technologies is a Private company.
-
What is the current valuation of Dynavax Technologies?
The current valuation of Dynavax Technologies is .
-
What is Dynavax Technologies’s current revenue?
The current revenue for Dynavax Technologies is .
-
How much funding has Dynavax Technologies raised over time?
Dynavax Technologies has raised $693M.
-
Who are Dynavax Technologies’s investors?
Alta Partners, Axiom Venture Partners, Azimuth Opportunity, BVCF, and Bain Capital Life Sciences are 5 of 38 investors who have invested in Dynavax Technologies.
-
Who are Dynavax Technologies’s competitors?
Valerio Therapeutics, Agenus, Adaptimmune Therapeutics, VBI Vaccines, and Zymeworks are some of the 41 competitors of Dynavax Technologies.
-
When was Dynavax Technologies acquired?
Dynavax Technologies was acquired on 10-Feb-2026.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process